# Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market - CNBC

## Metadata
| Field | Value |
|-------|-------|
| Source | CNBC |
| URL | https://news.google.com/rss/articles/CBMipAFBVV95cUxQbUIybWMzOFIwQmFDZ2RYX19Ja3JYR2xXc1k4TE41aHVrUXhVWHI3c1FuakFyODI1WnZRcnNqc3ZJSWdBNTBELXgzTElHd0pkRkpqSW8zX1d4V1A5eFhiNktELW1kblFVWU5hOVdqSUdsbzl5cHFEWFN6Qnl5SThuNnhlSlVVMHpaTHNaeXh4ZW93MG1ycGZRU2xZSGUwRjhUR1lfTg?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2026-01-02 07:00 |
| Category | GLP-1 |
| Relevance | 9/10 |
| Signal | neutral |

## Investment Summary
Novo Nordisk is facing competitive pressure in the GLP-1 obesity/diabetes market from Eli Lilly, highlighting market dynamics and potential investment opportunities in weight loss pharmaceuticals.

## Key Entities
Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
